165393-06-6
165393-06-6 結(jié)構(gòu)式
基本信息
3,8,9-三羥基-6H-苯并[C]色烯-6-酮
3,8,9-Trihydroxy-6H-benzo[c]chromen-6-one
3,8,9-Trihydroxy-6H-dibenzo[b,d]pyran-6-one
6H-Dibenzo[b,d]pyran-6-one, 3,8,9-trihydroxy-
物理化學(xué)性質(zhì)
安全數(shù)據(jù)
| 報(bào)價(jià)日期 | 產(chǎn)品編號(hào) | 產(chǎn)品名稱 | CAS號(hào) | 包裝 | 價(jià)格 |
| 2025/12/22 | HY-135897 | 尿石素C Urolithin C | 165393-06-6 | 5 mg | 620元 |
| 2025/12/22 | HY-135897 | 尿石素C Urolithin C | 165393-06-6 | 10mM * 1mLin DMSO | 680元 |
| 2025/12/22 | HY-135897 | 尿石素C Urolithin C | 165393-06-6 | 10mg | 1000元 |
常見問(wèn)題列表
Insulin secretion
L-type Ca
2+
channel
Reactive oxygen species (ROS)
Apoptosis
Urolithin C (20-100 μM; 1 hour; INS-1 cells) treatment enhances glucose-induced extracellular signal-regulated kinases 1/2 (ERK1/2) activation in INS-1 β-cells.
Urolithin C significantly inhibits the proliferation of PC12 cells. Urolithin C treatment actively increases the lactate dehydrogenase (LDH) release and lipid peroxidation malondialdehyde (MDA), stimulates reactive oxygen species (ROS) formation and mitochondrial membrane depolarization, and caused calcium dyshomeostasis.
Urolithin C treatment induces apoptosis and S phase cell cycle arrest.
Western Blot Analysis
| Cell Line: | INS-1 cells |
| Concentration: | 20 μM, 100 μM |
| Incubation Time: | 1 hour |
| Result: | Enhanced glucose-induced extracellular signal-regulated kinases 1/2 (ERK1/2) activation. |
The pharmacokinetics of Urolithin C (10 mg/kg; intraperitoneal administration) in male Wistar rat (140-160 g) are studied. The half-life of the terminal part is 11.3 h and the total clearance (CL/F) is 3.41 L/h/kg. The initial volume of distribution (V 1 /F) and the steady-state volume of distribution (Vss/F) are 0.831 L/kg and 55.6 L/kg, respectively.